Skip to content

Does Stellate ganglion block provide any benefit in the treatment of patients with moderate to severe anxiety who have failed standard treatment.

Stellate Ganglion Block in the Management of Treatment Resistant Anxiety Disorders: a randomized controlled trial. - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/02/063259
Enrollment
63
Registered
2024-02-28
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Stellate Ganglion Block: The participant will be positioned supine with the head turned to the contralateral side. The skin over the anterolateral aspect of the neck will be prepped wit

Sponsors

Sri Madhusudan Sai Institute of Medical Sciences and Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adults with treatment resistant anxiety disorder who score ?10 on GAD-7 questionnaire and are willing to consent.

Exclusion criteria

Exclusion criteria: 1. Participants unwilling to provide consent 2. Participants with known history of drug allergy to bupivacaine, lidocaine or depot methylprednisolone 3. Recent myocardial infarction 4. Patients on anti-coagulants or dual anti-platelet drugs 5. Glaucoma 6. Severe COPD 7. Cardiac conduction block

Design outcomes

Primary

MeasureTime frame
The primary outcome of the study will be to determine the effectiveness of Stellate Ganglion Block in reducing anxiety in patients with Treatment Resistant Anxiety Disorder as quantified by GAD-7 questionnaire at 4 weeks post treatment.Timepoint: At baseline At 4 weeks At 8 weeks

Secondary

MeasureTime frame
GAD-7 score at 12 weeks post treatmentTimepoint: 12 weeks post intervention;change in Hamilton Anxiety scale scoresTimepoint: Baseline 4 weeks post intervention 12 weeks post intervention;change in quality of lifeTimepoint: 4 weeks post intervention 12 weeks post intervention

Countries

India

Contacts

Public ContactDr Aiswarya

Sri Madhusudan Sai Institute of Medical Sciences and Research

niraj.gopinath@smsimsr.org9036119279

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026